<DOC>
	<DOCNO>NCT02485899</DOCNO>
	<brief_summary>The Phase 1/2 study ( 190-201 ) evaluate efficacy safety dose 300 mg/every week ( qow ) BMN 190 patient CLN2 . The dose regimen study ( 190-202 ) base result 190-201 study . The rationale phase 2 extension study provide patient complete 190-201 study option continue receive continue BMN 190 treatment . The 190-202 study open label extension protocol ass long-term safety efficacy .</brief_summary>
	<brief_title>A Multicenter , Multinational , Extension Study Evaluate Long-Term Efficacy Safety BMN 190 Patients With CLN2 Disease</brief_title>
	<detailed_description>BMN 190 recombinant form human tripeptidyl peptidase 1 ( TPP1 ) , enzyme deficient patient CLN2 disease ( also know classical late-infantile CLN2 , cLINCL , Jansky-Bielschowsky disease ) , form Batten Disease . As enzyme replacement therapy ( ERT ) , BMN 190 design restore TPP1 enzyme activity . BMN 190 design reduce progressive , pathologic accumulation lysosomal storage material , improve symptom disease . The Phase 1/2 study ( 190-201 ) evaluate efficacy safety dose 300 mg/every week ( qow ) BMN 190 patient CLN2 . The dose regimen study ( 190-202 ) base result 190-201 study . The rationale phase 2 extension study provide patient complete 190-201 study option continue receive continue BMN 190 treatment . The 190-202 study open label extension protocol ass long-term safety efficacy .</detailed_description>
	<mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
	<criteria>Must complete 48 week Study 190201 . Is willing able provide write , sign informed consent . Or , case patient age 18 ( age define regional law regulation ) , provide write assent ( require ) write informed consent , sign legally authorize representative , nature study explain , prior performance researchrelated procedure . Males female reproductive age practice true abstinence , define sexual activity , study 6 month study complete ( withdrawal study ) . If sexually active practice true abstinence , male female reproductive age must use highly effective method contraception participate study . If female , childbearing potential , must negative pregnancy test Screening Visit willing additional pregnancy test do study . Has loss 3 point combine motor language component Hamburg CLN2 rating scale Baseline Study 190201 Study Completion visit Study 190201 would benefit enrol study Investigator 's discretion . Has score 0 point combine motor language component Hamburg CLN2 rating scale . Is pregnant breastfeeding , Baseline , plan become pregnant ( self partner ) time study . Has use investigational product ( BMN 190 190201 ) , investigational medical device , within 30 day prior Baseline ; require use investigational agent prior completion schedule study assessment . Has concurrent disease condition would interfere study participation , pose safety risk , determine Investigator . Has condition , view Investigator , place patient high risk poor treatment compliance complete study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Late infantile Neuronal Ceroid Lipofuscinosis Type 2</keyword>
	<keyword>LINCL</keyword>
	<keyword>NCL2</keyword>
	<keyword>CLN2</keyword>
	<keyword>Jansky-Bielschowsky disease</keyword>
</DOC>